Parexel, TriNetX partner to advance RWD in clinical trials
By Leo Adler on July 1, 2020
Global contract analysis group (CRO) Parexel and healthcare analysis specialist TriNetX are collaborating on a undertaking looking for to enhance entry to and use of real-world information in clinical analysis. Together with healthcare information analysts at Datavant, the companions purpose to join to healthcare information, in order to help growth of richer insights in the hopes of accelerating the execution of analysis.
According to the businesses, the built-in providing will leverage Datavant’s privacy-protecting linking know-how, in order to join Parexel’s research operations information with de-identified information from TriNetX’s world healthcare group community. The intent is to successfully streamlining entry to RWD, to assist improve clinical trials and produce new therapies to market quicker.
Michelle Hoiseth, chief information officer for Parexel, mentioned the worldwide pandemic has induced curiosity in RWD and different superior applied sciences to unfold in the trade.
“Our industry has been moving toward more widespread use of real-world data to support clinical development, accelerated by the COVID-19 crisis and informed by new regulatory guidance,” she mentioned. “Access to richer real-world data on-demand has become even more critical.”
“Together with TriNetX and Datavant, Parexel has taken an important step forward in its strategy to connect data in a manner that complies with privacy regulations and our data policies at the patient level, bringing the right patient to the right trial at the right time to significantly enhance and accelerate clinical development,” Hoiseth added.
Leo Adler is scientist, writer and poet. His mother is an Artist and father is preschool teacher. He attain a bachelor's degree in English. He has 3 years experience in online news writing. Now he is works as a news writer on Guru Online News.